We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Increase in serum lactate dehydrogenase (LDH) in COVID-19 patients between November 2020 and March 2021.
- Authors
Feto, Amila; Bečić, Elma; Herenda, Naida; Kadić, Belma; Muftić, Amela; Katica-Mulalić, Amela
- Abstract
Introduction: COVID-19 has reached pandemic proportions and become a global health challenge. Although in most patients with COVID-19 the disease is mildly symptomatic, in some patients it significantly worsens, causing multi-organ failure leading to death. Available biomarkers, especially those that are routinely tested, allow us to figure out development of a severe clinical picture of the disease. Lactate dehydrogenase (LDH) is an intracellular enzyme involved in anaerobic glycolysis that catalyzes the oxidation of pyruvate to lactate. Elevated LDH indicates tissue hypoperfusion and degree of the disease, therefore it can have an effect on the prognosis. LDH could be a potential prognostic biomarker in patients with COVID-19. The aim of this retrospective analysis was to figure the prognostic significance of elevated LDH in patients with COVID-19. Materials and methods: in this retrospective study, we observed 191 patients hospitalized in the Isolation Ward for hospital treatment of patients with COVID-19 in the period from November 2020 to March 2021, of whom 98 survived and 93 died. Patients' age, sex, hospitalization days, intubation day from the hospital admission, serum lactate dehydrogenase levels at admission and discharge with other parameters, initial saturation, comorbidities and the patients' outcome were monitored. Results: in the group of patients who died, the average age was 69.94±10.85 compared to 59.38±14.04 in the group of patients who survived. More frequent use of antibiotics was expressed in the group of those who had died before hospitalization in 60% compared to 40.8% in the group of those who survived. Comorbidities were present in the group of patients who died in 86.0% compared to 57.1% in the group of those who survived. LDH values at admission were not significantly different, while LDH values at discharge/last examination were significantly higher in the group of patients who died. Also, LDH values in the group of survived patients were decreased by-192.73±231.52 of average value, and increased by 133.67±366.23 on average value in the group of patient who died. Conclusion: serum LDH was validated for its potential usefulness as markers for evaluating clinical severity and monitoring treatment response in COVID-19 pneumonia.
- Subjects
CORONAVIRUS diseases; LACTATE dehydrogenase; BIOLOGICAL tags; GLYCOLYSIS; PYRUVATES; LACTATES
- Publication
Medical Journal / Medicinski Žurnal, 2022, Vol 28, Issue 3/4, p121
- ISSN
1512-5866
- Publication type
Article